Business Context and Reporting Period
Company: Microbot Medical Inc. (NASDAQ: MBOT)
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: Microbot is a pre-clinical medical device company developing the LIBERTY® Endovascular Robotic Surgical System, a fully disposable robotic system for minimally invasive endovascular procedures. The company has no commercial revenue to date and is focused on completing pivotal human clinical trials.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,465) | $(4,836) | $(5,140) |
| Operating Loss | $(2,511) | $(4,895) | $(5,243) |
| Research & Development Expenses | $(1,417) | $(2,586) | $(2,982) |
| General & Administrative Expenses | $(1,094) | $(2,309) | $(2,261) |
| Cash & Cash Equivalents | $2,465 | $2,465 | N/A |
| Marketable Securities | $3,997 | $3,997 | N/A |
| Total Liquidity (Cash + Securities) | $6,462 | $6,462 | N/A |
| Net Working Capital | $5,797 | $5,797 | N/A |
| Net Loss Per Share (Diluted) | $(0.17) | $(0.33) | $(0.60) |
Note: The company has no debt obligations listed on the balance sheet other than lease liabilities ($148 total). Total liabilities were $1,379 as of June 30, 2024.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss for the six months ended June 30, 2024, decreased by approximately $304,000 compared to the same period in 2023, primarily due to reduced R&D expenses from a cost reduction plan and government grant deductions.
- Legal Settlement Resolution: The company resolved a significant lawsuit (Empery Asset Master Ltd.) in Q1 2024. The settlement involved a cash payment of $1.1 million (covered by insurance) and the issuance of 1,005,965 shares of common stock. This removed a $2.2 million liability and a $1.3 million receivable from the balance sheet.
- Capital Raises: The company raised approximately $4.47 million in net proceeds from financing activities in the first six months of 2024, compared to $6.72 million in the same period in 2023. This included a registered direct offering in June 2024.
- Share Count Increase: Shares outstanding increased from 11.7 million (Dec 31, 2023) to 15.97 million (June 30, 2024) due to capital raises and the stock component of the legal settlement.
Outlook, Risks, and Management Commentary
- Clinical Milestones: The company received FDA approval in June 2024 to commence its pivotal human clinical trial for the LIBERTY system. Three major hospitals (Brigham and Women's, Baptist Hospital of Miami, Memorial Sloan Kettering) have enrolled. The company anticipates FDA 510(k) clearance in the first half of 2025 and CE Mark approval in the second half of 2026.
- Going Concern Warning: Management states that conditions raise substantial doubt about the company's ability to continue as a going concern. They believe current funds are sufficient for less than one year of operations. Additional capital will be required to complete clinical trials and commercialization.
- War in Israel: The company's R&D operations are primarily based in Israel. While no material adverse effect has been reported to date, ongoing military operations pose risks to supply chains, subcontractor availability, and flight logistics. The company has no specific contingency plans for escalation.
- Future Funding: The company intends to raise capital through future public/private issuances and its reinstated At-the-Market (ATM) agreement. Subsequent to the reporting period, the company raised an additional $584,000 via the ATM.
Investor Verification Checklist
- Cash Runway: Verify the specific duration of the "less than one year" liquidity estimate and the timeline for the next anticipated capital raise.
- Clinical Trial Enrollment: Monitor the pace of patient enrollment in the pivotal FDA-approved clinical trial to ensure the 2025 clearance timeline remains viable.
- Israel Operations: Assess any updates regarding the impact of the ongoing conflict in Israel on the company's R&D timeline and supply chain.
- Dilution Risk: Review the terms of the recent registered direct offerings and the ATM agreement to understand potential future dilution to existing shareholders.
- Government Grants: Confirm the status of repayable grants from the Israeli Innovation Authority (IIA) and the Ministry of Economy, noting that repayment is contingent on future sales.